Kenneth Walsh Selected Research

human FSTL1 protein

9/2015	Epicardial FSTL1 reconstitution regenerates the adult mammalian heart.
10/2012	Therapeutic impact of follistatin-like 1 on myocardial ischemic injury in preclinical models.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth Walsh Research Topics

Disease

36	Obesity 07/2022 - 12/2003
25	Inflammation (Inflammations) 01/2021 - 01/2002
20	Ischemia 01/2018 - 07/2004
16	Hypertrophy 01/2019 - 05/2002
16	Insulin Resistance 12/2017 - 11/2004
15	Cardiovascular Diseases (Cardiovascular Disease) 07/2022 - 04/2007
14	Reperfusion Injury 02/2016 - 04/2003
13	Heart Failure 01/2022 - 10/2002
13	Myocardial Infarction 01/2020 - 10/2005
12	Atherosclerosis 01/2021 - 12/2003
10	Neoplasms (Cancer) 07/2022 - 01/2002
10	Fibrosis (Cirrhosis) 10/2018 - 05/2006
10	Cardiomegaly (Heart Hypertrophy) 01/2018 - 12/2004
10	Hypoxia (Hypoxemia) 07/2013 - 08/2003
7	Hypoadiponectinemia 04/2013 - 12/2003
6	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 12/2003
6	Myocardial Ischemia (Ischemic Heart Diseases) 05/2016 - 10/2005
6	Hypertension (High Blood Pressure) 09/2010 - 06/2006
6	Hyperplasia 02/2007 - 08/2002
5	Type 2 Diabetes Mellitus (MODY) 03/2016 - 12/2003
5	Infarction (Infarctions) 01/2016 - 10/2005
5	Alzheimer Disease (Alzheimer's Disease) 07/2014 - 02/2004
4	Cardiotoxicity 01/2021 - 10/2002
4	Diabetes Mellitus 03/2016 - 01/2009
4	Autoimmune Diseases (Autoimmune Disease) 01/2009 - 01/2003
3	Glucose Intolerance 07/2022 - 07/2010
3	Cardiomyopathies (Cardiomyopathy) 01/2021 - 03/2004
3	Muscular Dystrophies (Muscular Dystrophy) 01/2016 - 01/2009
3	Heart Diseases (Heart Disease) 01/2016 - 11/2007
3	Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left) 12/2015 - 01/2010
3	Inclusion Body Myositis 07/2014 - 10/2006
3	Vascular System Injuries 07/2014 - 08/2002
3	Starvation 01/2013 - 04/2004
3	Atrophy 05/2012 - 04/2004
3	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2012 - 06/2006
3	Metabolic Diseases (Metabolic Disease) 02/2011 - 07/2008
3	Vascular Remodeling 09/2010 - 12/2003
3	Pathologic Neovascularization 01/2010 - 08/2006
3	Vascular Diseases (Vascular Disease) 01/2009 - 12/2003
2	Left Ventricular Dysfunction 10/2018 - 12/2015
2	Mitochondrial Diseases (Mitochondrial Disease) 12/2015 - 05/2003
2	Carcinogenesis 10/2014 - 11/2002
2	Myositis (Idiopathic Inflammatory Myopathies) 07/2014 - 01/2014
2	Fatty Liver 04/2013 - 02/2012
2	Acute Coronary Syndrome 10/2012 - 08/2012

Drug/Important Bio-Agent (IBA)

46	AdiponectinIBA 12/2015 - 12/2003
16	AdipokinesIBA 01/2022 - 12/2003
16	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
13	Insulin (Novolin)FDA Link 10/2018 - 07/2002
13	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 12/2014 - 01/2002
11	CytokinesIBA 02/2020 - 01/2003
9	Glucose (Dextrose)FDA LinkGeneric 04/2015 - 11/2004
9	Hormones (Hormone)IBA 04/2013 - 04/2007
7	LipidsIBA 07/2015 - 11/2004
6	FollistatinIBA 01/2016 - 03/2011
6	AMP-Activated Protein KinasesIBA 12/2015 - 08/2003
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2015 - 11/2003
5	Blood Proteins (Serum Proteins)IBA 01/2022 - 08/2006
5	DNA (Deoxyribonucleic Acid)IBA 02/2020 - 05/2003
5	Angiotensin IIIBA 01/2020 - 05/2002
5	Sirolimus (Rapamycin)FDA Link 12/2009 - 08/2006
4	Interleukin-6 (Interleukin 6)IBA 01/2021 - 12/2003
4	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 10/2002
4	LigandsIBA 01/2019 - 11/2003
4	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019 - 07/2002
4	Protein Kinases (Protein Kinase)IBA 07/2013 - 08/2003
4	Messenger RNA (mRNA)IBA 05/2012 - 06/2006
4	Amyloid beta-PeptidesIBA 12/2008 - 02/2004
4	Fas Ligand Protein (Fas Ligand)IBA 09/2006 - 01/2002
3	Sucrose (Saccharose)IBA 01/2020 - 01/2015
3	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 01/2019 - 05/2006
3	Peptides (Polypeptides)IBA 10/2018 - 11/2005
3	MyokinesIBA 01/2018 - 01/2009
3	WD repeat containing planar cell polarity effectorIBA 02/2016 - 07/2010
3	CollagenIBA 01/2016 - 05/2006
3	Phosphotransferases (Kinase)IBA 12/2015 - 04/2004
3	Protein Isoforms (Isoforms)IBA 12/2014 - 06/2007
3	Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA 07/2013 - 01/2009
3	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2013 - 07/2002
3	Mechanistic Target of Rapamycin Complex 1IBA 01/2013 - 03/2009
3	Glycoproteins (Glycoprotein)IBA 10/2011 - 01/2009
3	salicylhydroxamic acid (SHAM)IBA 09/2010 - 05/2006
3	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 12/2008 - 04/2005
3	erucylphosphocholineIBA 05/2008 - 08/2005
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 09/2006 - 12/2003
2	ChemokinesIBA 01/2019 - 02/2012
2	LDL Receptors (LDL Receptor)IBA 01/2017 - 05/2011
2	Nitric Oxide (Nitrogen Monoxide)FDA Link 03/2016 - 09/2010
2	Caspase 3 (Caspase-3)IBA 12/2015 - 05/2003
2	human FSTL1 proteinIBA 09/2015 - 10/2012
2	AlbuminsIBA 03/2015 - 12/2003
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 07/2014 - 08/2002
2	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 02/2014 - 10/2005
2	ProstaglandinsIBA 02/2014 - 10/2005
2	H-cadherin (T-cadherin)IBA 08/2013 - 12/2010
2	AndrogensIBA 07/2013 - 07/2010
2	Androgen Receptors (Androgen Receptor)IBA 07/2013 - 07/2010
2	LipopolysaccharidesIBA 10/2012 - 01/2012

Therapy/Procedure

8	Therapeutics 07/2022 - 06/2006
3	Ligation 10/2019 - 06/2007